Journal
METABOLIC SYNDROME AND RELATED DISORDERS
Volume 16, Issue 8, Pages 390-394Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/met.2018.0075
Keywords
obesity; pharmacotherapies; glucagon; GLP-1
Categories
Funding
- NIH [R01-DK67071]
- Endoscopy and Physiology Core Laboratory, CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of National Institutes of Health (NIH) [UL1-TR002377]
Ask authors/readers for more resources
The objective of this review is to examine advances in the development of combination therapies for the treatment of obesity beyond diet or lifestyle interventions. Experimental combination pharmacotherapies include combinations of pramlintide and phentermine as well as amylin and bupropion-naltrexone. Incretin and pancreatic hormones generally inhibit upper gastrointestinal motor functions, and combinations showing efficacy in obesity are coadministration of glucagon-like peptide-1 (GLP-1) with glucagon, a unimolecular dual incretin of PEGylated GLP-1/GIP coagonist, the combination of GLP-1 and PYY3-36, and, in proof of concept studies, combined infusions of GLP-1, peptide YY, and oxyntomodulin. Among bariatric procedures, repeat intragastric balloon (IGB) treatments are more efficacious than IGB plus diet, and endoscopic intervention can enhance the effects of Roux-en-Y gastric bypass when weight regain occurs. A first trial has provided promising results with combination of IGB plus the GLP-1 analog, liraglutide, compared to the balloon alone. Thus, combination therapies for the treatment of obesity hold promise for introduction into clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available